Welcome to our dedicated page for Koru Med Sys SEC filings (Ticker: KRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
KORU Medical Systems filings document a Nasdaq-listed medical technology issuer focused on large-volume subcutaneous infusion products. The disclosures identify its common stock, operating results, earnings-release exhibits, non-GAAP measures such as adjusted EBITDA and adjusted diluted EPS, and the Freedom System product family used in home self-administration and ambulatory infusion settings.
Its SEC record also covers proxy governance, board and stockholder-meeting procedures, officer and compensation arrangements, and material agreements tied to the business. Recent 8-K filings describe credit-facility arrangements and manufacturing and supply agreements for subassemblies, needle sets, and tubing products.
Joseph M. Manko Jr., a director and reported 10% owner, filed a Form 4 for KORU Medical Systems, Inc. (KRMD). The filing shows a transaction dated 09/30/2025 where he acquired 3,916 shares of Common Stock at a reported price of $0, and reports 5,871,335 shares beneficially owned indirectly through Horton Capital Partners Fund, LP. The Form also reports a disposition of 517,200 shares.
The Form 4 is signed by Mr. Manko with signature dates of 10/02/2025. The filing references an Exhibit 99.1 for explanations of two notes tied to the reported acquisition and indirect ownership. No additional financial metrics, option holdings, or exercise/expiry dates are disclosed in the filing text provided.
KORU Medical Systems, Inc. filed a Form S-8 to register common stock related to equity awards granted to its incoming Chief Commercial Officer. The company granted an Individual Restricted Stock Agreement for 300,000 shares and a Non‑Qualified Stock Option Award covering 600,000 shares, granted July 28, 2025 and August 1, 2025 respectively, each subject to vesting and potential acceleration, to Adam Kalbermatten as an inducement to join as CCO. The registration statement specifically registers the common stock issuable upon exercise of those options and incorporates by reference the company’s annual report and other Exchange Act filings and the description of its common stock. The filing also discloses charter provisions limiting director liability and indemnification provisions, and notes that indemnification for Securities Act liabilities may be unenforceable under SEC precedent.
Linda M. Tharby, who serves as President, CEO and a director of KORU Medical Systems (KRMD), was awarded equity under the company’s 2024 Omnibus Equity Incentive Plan as part of the 2025 Long-Term Incentive Program. The awards reported include 55,911 restricted stock units that vest one-fourth on May 12, 2026 and annually thereafter, 111,729 performance-based restricted stock units payable at target (the payout may range from 0%-150% of the reported amount and is further multiplied by 0.5x–1.5x depending on performance) that vest based on achievement as of December 31, 2027, and an option to buy 94,772 shares at a $3.21 exercise price expiring May 12, 2035 with one-fourth vesting annually beginning May 12, 2026.
The transaction date for these awards is reported as 05/12/2025. The filing notes that vesting may accelerate upon a change in control and clarifies the reported RSU amounts represent contingent rights or target awards rather than immediately issued shares.
KORU Medical Systems insider award summary: Christopher Pazdan, the company’s Chief Operating Officer, received equity awards under the 2024 Omnibus Equity Incentive Plan as part of the 2025 Long-Term Incentive Program on 05/12/2025. The awards include two restricted stock unit grants of 21,308 RSUs each (total 42,616 RSUs); one grant vests time-based one-fourth on 05/12/2026 and annually thereafter, the other vests based on performance measured as of 12/31/2027 with potential payout from 0% to 150% of target and specified multipliers, and both convert to one share per vested unit. Pazdan also received an option for 36,077 shares with a $3.21 exercise price that vests one-fourth on 05/12/2026 and annually thereafter and expires on 05/12/2035. The filing states these awards were granted pursuant to the Company’s equity plan.
Thomas Edward Adams, Chief Financial Officer of KORU Medical Systems (KRMD), received equity awards under the company’s 2024 Omnibus Equity Incentive Plan as part of the 2025 Long-Term Incentive Program. The grants include 32,773 restricted stock units that vest one-fourth on May 12, 2026 and annually thereafter, 32,773 performance-based restricted stock units payable at target (the Reporting Person could earn 0%-150% of the reported amount, further multiplied by between 0.5 to 1.5) based on performance as of December 31, 2027 and vesting at 100% on a change in control prior to that date, and an option to purchase 55,583 shares with a stated exercise price of $3.21 that vests one-fourth on May 12, 2026 and annually thereafter. Each reported position is listed as direct ownership.
KORU Medical Systems insider award summary: Adam R. Kalbermatten, the company’s Chief Commercial Officer, received a 300,000-share restricted stock award as an employment inducement and an option to buy 600,000 shares. The restricted shares vest 25% annually beginning July 28, 2026, subject to acceleration under his employment agreement. The option carries a $3.44 exercise price, a listed expiration of August 1, 2035, and a vesting schedule of one-fourth on August 1, 2026 and on each anniversary thereafter for three years.
What this means: The grants align compensation with future service and performance but create potential dilution of up to 900,000 shares if fully issued and exercised. Both holdings are reported as directly owned by the reporting person.
KORU Medical Systems, Inc. filed an initial insider ownership report for its Chief Commercial Officer, Adam R. Kalbermatten. The Form 3 shows that, as of the event date of 07/28/2025, he beneficially owned 0 shares of KORU Medical common stock in direct ownership. This filing establishes his baseline reported ownership as a newly reported officer of the company.